Our bodies can recover from many maladies given time and a healthy immune system. Israel has been working for years on mesenchymal stromal cells (MSCs) to repair and reverse the effects of various diseases.
https://www.newsmax.com/scitech/covid-19-lungs-medicine-research-and-development/2020/05/12/id/967160/ The Israeli company, Bonus BioGroup used MSCs in a new drug to promote regeneration of lung tissue that had been damaged by acute respiratory distress. It is possible that this drug might be an effective agent to combat COVID-19 patients with severe respiratory complications. Additionally, it could be used in a variety of lung and respiratory infections.
MSCs and COVID-19
https://www.jpost.com/HEALTH-SCIENCE/Israeli-company-says-its-COVID-19-drug-completely-prevents-lung-damage-627806?utm_source=Jeeng The drug using MSCs is not a vaccination and does not prevent coronavirus infection. It does provide the body with the ability to help itself heal damaged lung tissue that is typical in many severe cases of COVID-19.
As the pandemic waxes and wanes, there will be a need for more arrows in the quivers of medical professionals to effectively address the disease on both the front and back end. This drug demonstrated the regeneration of healthy lung tissue from the inflamed and disease-ravaged tissue.
I was told this week that a good friend of mine is in a local ICU with COVID-19 and pneumonia. He is elderly with pre-existing conditions. Pneumonia associated with the viral infection would be a perfect example of treating the back end of the coronavirus.
Our immune systems are supposed to protect us. However, many patients have experienced a cytokine storm in which the body wages war upon itself. The exact cause and progress have not been documented well enough and tested to know the exact details of why similar patients suffer from severe respiratory infections and others do not.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527296/ is a recent article by the US National Library of Medicine, National Institutes of Health, that summarizes the progression of cytokine storms in COVID-19 patients. It is a technical article and covers several pathological pathways that facilitate the severe respiratory effects of many COVID-19 patients.
Their conclusion suggested the IL-6 (Interleukin-6) levels are highly correlated with lethal complications of COVID-19 and proposed that it is a valuable biomarker for determining the severity of the respiratory complication.
MSCs and the FDA
https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/blood-derived-products/mesenchymal-stem-cells/ MSCs have been studied for years in both regenerative and immunomodulatory areas. Current COVID-19 Treatment Guidelines in the United States recommends against the use of MSCs except in approved clinical trials.
MSCs are present in most human tissues. They can self-renew by dividing and can differentiate into many different types of tissues. Their ability to do this is the source of the power for the regeneration of diseased cells to return to the original condition.
Without placebo-controlled, randomized, double-blind clinical tests, the FDA does not put its stamp of approval on any potential antiviral drug, especially anything regarding COVID-19.
Maybe it is a good thing this drug and testing is not being done in the United States. This Israeli drug does not prevent or mitigate any infection caused by the SARS-CoV-2 virus. It is an after-treatment of acute and severe respiratory complications of which COVID-19 can cause.
Some drugs appear to be more welcome than others when it comes to a pandemic fight!
Live Longer & Enjoy Life! – Red O’Laughlin – RedOLaughlin.com